CG Oncology logo

CG Oncology

Attacking Bladder Cancer for a Better Tomorrow

121 employees · est. 2010 · Irvine, United States

VS
Nouscom  logo

Nouscom

57 employees · est. 2015 · Switzerland

CG Oncology is the older company (2010 vs 2015).

Side-by-Side Comparison

CG Oncology Nouscom
Founded
2010 older 2015
Headquarters
Irvine, United States Switzerland
Employees
121 57
Industry
Biotechnology, Health Care Biotechnology, Health Care, Health and Wellness
Funding Stage
Series F Series C
Total Funding
$317.57M $128.50M
Funding Rounds
7 4
Services
Not tracked yet Not tracked yet
Target Customers
Not tracked yet Not tracked yet
Taxonomy
Oncolytic Immunotherapy, Bladder Cancer, Clinical-Stage Biopharmaceutical, CG0070, Immunotherapies, BioSante Pharmaceuticals, NMIBC, Phase 3 Trial, Keytruda, Opdivo, Urologic Cancer, Clinical Trial, Biopharmaceutical Company, Immunotherapy Agent, Patient Therapies Biotech, Startup, Immunotherapeutics, Cancer Treatment, Oncology, Biomedical, Biopharmaceuticals, Cell Targeting, Cancer Research, Innovation
Website
cgoncology.com nouscom.com
CG Oncology logo

About CG Oncology

CG Oncology is a late-stage clinical biopharmaceutical company, founded in 2010, focusing on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is in a Phase 3 trial for the t...

Nouscom  logo

About Nouscom

Nouscom is a biotech startup founded in 2015 and headquartered in Switzerland. The company is focused on developing highly effective immunotherapeutics targeting cancerous cells. Its last funding round, a €75.80M Series C investment on 21 March 2024, saw participation from a diverse group of investo...

We will tell you when either one moves

BounceWatch watches CG Oncology and Nouscom for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at CG Oncology and Nouscom — by email.

Frequently Asked Questions

CG Oncology — Attacking Bladder Cancer for a Better Tomorrow. Nouscom . Both companies operate in related markets but may differ in funding stage, team size, and product focus.
CG Oncology has raised $317.57M while Nouscom has raised $128.50M.
CG Oncology and Nouscom operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare CG Oncology with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at CG Oncology on 11 Sep 2024, and Nouscom on 11 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy